Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

679

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 589–600 of 679 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Active filters: "hormone receptor-positive" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18; Biological · Drug · Other + 2 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
U.S. locations: 10
States / cities: Monterey, California • Santa Monica, California • Orlando, Florida + 7 more

Conditions: Breast Cancer
Interventions: Anastrozole, flaxseed, Placebo; Drug · Dietary Supplement
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: bevacizumab, letrozole; Biological · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions: Docetaxel with Cytoxan, Dexamethasone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: High Risk, Breast Cancer, Positive Nodes, Cyclophosphamide, Doxorubicin
Interventions: Doxorubicin, Cyclophosphamide, G-CSF, tamoxifen, ciprofloxacin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: exemestane, triptorelin pamoate, capecitabine, methotrexate, vinorelbine tartrate, paclitaxel, therapeutic conventional surgery, radiation therapy, laboratory biomarker analysis; Drug · Procedure · Radiation + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 172
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more

Conditions: Breast Cancer
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Breast Cancer, Cancer of the Breast, Neoplasms, Breast
Interventions: Estrace, Anastrozole; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: HER-2/neu peptide vaccine; Biological
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Seattle, Washington

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

About this Breast Cancer clinical trials directory page